Supervised Injectable Opioid Treatment for the Management of Opioid Dependence
- 310 Downloads
Since the 1990s, there have been seven clinical trials, and considerable clinical experience, in supervised injectable opioid treatment (SIOT) for individuals who, despite previous treatments, continue to inject illicit heroin and experience harmful health and social consequences. Most studies prescribed pharmaceutical heroin (diacetyl morphine, or DAM). This paper critically reviews randomised trials, long-term follow-up studies and qualitative reports of SIOT, and briefly reviews evidence regarding other medications used in injectable treatment as an alternative to DAM. It seeks to identify critical, unresolved issues regarding this treatment. Randomised trials comparing DAM with oral methadone (OM) report that while in treatment, participants randomised to DAM used less street heroin; reported spending less money on drugs, committed fewer crimes, and experienced improved health. Similar findings pertain to SIOT with hydromorphone. Because of the risks of overdose, diversion, and misuse, all recent trials of injected DAM involved supervised administration. This contributes to treatment being expensive to deliver. There is conflicting evidence regarding societal cost effectiveness, with some studies estimating that the reduction in crime more than compensates for the expense of the treatment. The critical, unresolved issues concerning this modality of treatment relate to the way in which it is approached—either as a medium-term, intensive intervention where other treatment has failed, designed to bring people into conventional opioid agonist treatment (OAT); or an indefinite support aimed at reducing social and personal harm. The former seems in line with the available findings on long-term effectiveness of SIOT and might be more acceptable given its rather moderate cost.
Compliance with Ethical Standards
This work was completed without external funding.
Conflict of Interest
Dr. Bell is employed by Uniting MSIC to develop a clinical trial of SIOT. In the last 5 years he has received research support from Reckittbenckiser, served on an Advisory Board for Indivior, has received speaker fees and support to attend conferences from Indivior. Dr. Belackova is employed by Uniting MSIC in developing a trial of SIOT. Prof. Lintzeris has provided consultancies for Indivior and Mundipharma on unrelated projects.
- 1.United Nations Office on Drugs and Crime. World drug report. Vienna: United Nations; 2012.Google Scholar
- 2.United Nations Office on Drugs and Crime. World drug report. Vienna: United Nations; 2017.Google Scholar
- 22.Moffatt S, Weatherburn D, Donnelly N. What caused the recent drop in property crime? Crime Justice Bull. 2005;85:2.Google Scholar
- 26.Public Health England. Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health/Population Health/Healthy Behaviours; 2017.Google Scholar
- 35.Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375(9729):1885–95.CrossRefPubMedCentralPubMedGoogle Scholar
- 38.Strang J, Groshkova T, Metrebian N. Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. Luxembourg: Publications Office of the European Union; 2012.Google Scholar
- 40.BCCS. Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver: British Columbia Centre on Substance Use, Ministry of Health; 2017.Google Scholar
- 41.Rook EJ. Pharmacokinetics and pharmacodynamics of diacetylmorphine in opioid dependent patients. Utrecht: Faculteit Geneeskunde, Universiteit Utrecht; 2003.Google Scholar
- 44.Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5–14.CrossRefPubMedCentralPubMedGoogle Scholar
- 45.Naber D, Haasen C. The German Model project for heroin-assisted treatment of opioid dependent patients—a multi-site, randomised controlled treatment study Part 1. Hamburg: Centre for Interdisciplinary Addiction Research of Hamburg University; 2006.Google Scholar
- 46.Metrebian N, Groshkova T, Hellier J, Charles V, Martin A, Forzisi L, et al. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction. 2015;110(3):479–90.CrossRefPubMedCentralPubMedGoogle Scholar
- 50.Naber D, Haasen C. The German Model project for heroin-assisted treatment of opioid dependent patients—a multi-site, randomised controlled treatment study Part 2. Hamburg: Centre for Interdisciplinary Addiction Research of Hamburg University; 2006.Google Scholar
- 60.Demaret I, Litran G, Magoga C, Deblire C, Dupont A, De Roubaix J, et al. Why do heroin users refuse to participate in a heroin-assisted treatment trial? Heroin Addict Relat Clin Prob. 2014;41–48.Google Scholar
- 61.Zinberg NE. Drug, set, and setting: the basis for controlled intoxicant use. New Haven: Yale University Press; 1984.Google Scholar
- 63.Bell J. Delivering effective methadone treatment. In: Ward J, Mattick RP, Hall W, editors. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998.Google Scholar
- 64.Oviedo-Joekes E, Palis H, Marchand K, Guh D, MacDonald M, Harrison S, et al. Characteristics and response to treatment among Aboriginal people receiving treatment with injectable opioids for the treatment of long-term opioid-dependency. Int Perspect Subst Use Health Outcomes, Chicago; 2015.Google Scholar